The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital


22 Mar 2021

Sino-Australia COVID 19 Seminar Series part two: Understanding SARS CoV 2 Immunity in a Pandemic

Add to my calendar 30/03/2021 4:00 pm 30/03/2021 5:00 pm Australia/Melbourne Sino-Australia COVID 19 Seminar Series part two: Understanding SARS CoV 2 Immunity in a Pandemic Online DD/MM/YYYY

30 Mar 2021
4.00 - 5.00pm


Please join the collaborative webinar between the Doherty Institute and Fudan University. Hosted by Professor Katherine Kedzierska and with presentations from Assistant Professor Rong Zhang and Dr Amy Chung.

Click this link to attend:

Dr Rong Zhang

Dr. Rong Zhang is an assistant professor at the Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, China. Dr. Zhang completed his Ph.D. training at both the Chinese Academy of Agricultural Sciences and the University of Pennsylvania where he was a visiting student working on the pathogenesis of mouse hepatitis virus. The research interest in Zhang lab at Fudan University mainly focuses on the interplay between virus and host factors and understanding the host cell/tissue tropism and cross-species transmission of medically important emerging and re-emerging viruses, such as coronaviruses and arboviruses.

Dr Amy Chung

Dr Amy Chung completed her PhD at the University of Melbourne in 2011 and conducted a postdoc at the Ragon Institute of Massachussetts General Hospital (MGH), Massachussetts Institute of Technology (MIT) and Harvard. She returned to the University of Melbourne in 2015 and established her own laboratory in 2019. Her research focuses upon the application of cutting-edge experimental technologies to holistically examine functional antibodies against a range of infectious diseases including HIV, Mycobacterium Tuberculosis, Malaria and Influenza. This research can be used to design future antibody-based vaccines and can contribute to the generation of improved monoclonal antibody therapeutics.


This seminar series is proudly supported by the National Foundation for Australia-China Relations